CeriBell Inc. (CBLL)
CBLL trades on Nasdaq in Health Care, Biotechnology: Electromedical & Electrotherapeutic Apparatus. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1861107/000119312526067238/0001193125-26-067238-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CBLL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Country | United States |
| IPO year | 2024 |
| SEC CIK | 0001861107 |
| SEC industry code | Electromedical & Electrotherapeutic Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $89.1M |
| Net income | -$53.4M |
| Operating income | -$58.4M |
| Net margin | -60.0% |
| Operating margin | -65.6% |
| Revenue growth | +36.1% |
| Cash | $40.5M |
| Total assets | $195.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 11.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-03 |
| Cash and burn | $42.0M cash; operating cash flow -$14.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 38,835,010 (2026-10-30); 37,095,690 a year earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, San Jose, California, United States | PCAOB Form AP 2026-03-05 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $22.9M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $29.3M | -$21.4M | -$13.1M | $42.0M | $20.0M | $108.7M | 10-Q 2026-11-03 |
| Q2 2026 2026-06-30 | $28.1M | -$19.3M | -$12.9M | $32.7M | $20.0M | $102.0M | 10-Q 2026-08-10 |
| Q1 2026 2026-03-31 | $26.5M | -$19.7M | -$19.3M | $45.3M | $19.9M | $95.1M | 10-Q 2026-05-11 |
| Q4 2025 2025-12-31 | $24.8M | -$13.5M | -$10.8M | $40.5M | $19.8M | $89.1M | 10-K 2026-02-24 |
| Q3 2025 2025-09-30 | $22.6M | -$13.5M | -$11.1M | $23.7M | $19.7M | $82.8M | 10-Q 2026-11-03 |
| Q2 2025 2025-06-30 | $21.2M | -$13.6M | -$7.5M | $40.1M | $19.7M | $77.4M | 10-Q 2026-08-10 |
| Q1 2025 2025-03-31 | $20.5M | -$12.8M | -$11.4M | $153.4M | $19.6M | $71.5M | 10-Q 2026-05-11 |
| Q4 2024 2024-12-31 | $18.5M | -$12.6M | -$10.0M | $194.4M | $19.6M | $65.4M | 10-K 2026-02-24 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2025-11-04 |
| Latest annual report | 10-K | 2026-02-24 |
| Latest quarterly / interim | 10-Q | 2026-11-03 |
| Latest current report | 8-K | 2026-11-03 |
| Latest proxy | DEFA14A | 2026-04-20 |
Source: SEC EDGAR submissions feed, 313 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.7% |
| 1 month | 0.0% |
| 3 months | +12.4% |
| Year to date | +19.2% |
| 1 year | +109.3% |
| From 52-week high | -7.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Electromedical & Electrotherapeutic Apparatus
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| INMD | InMode Ltd. | $13.15 | -0.90% | $755.9M |
| CNMD | CONMED Corporation | $49.35 | -2.45% | $1.5B |
| CV | CapsoVision Inc. | $6.47 | +7.30% | $346.9M |
| TMDX | TransMedics Group Inc. | $92.21 | +0.91% | $3.2B |
| AXGN | Axogen Inc. | $55.38 | -0.98% | $3.3B |
| LIVN | LivaNova PLC | $92.44 | +1.23% | $5.1B |
| ELMD | Electromed Inc. | $23.10 | -5.02% | $188.8M |
| FOCL | EDAP TMS S.A. | $3.17 | -2.39% | $149.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier